-
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-08-09 10:47:51ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus
-
DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-07-08 09:52:59DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-25 10:28:57DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:18:08DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-06-14 09:12:57DESTINY-Breast09 Head-to-Head First-Line Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive
-
DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant GliomaDaiichi Sankyo2021-06-11 17:41:55DELYTACT® Oncolytic Virus G47∆ Approved in Japan for Treatment of Patients with Malignant Glioma
-
Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma and Adult T-Cell Leukemia/LymphomaDaiichi Sankyo2021-06-11 09:11:05Valemetostat Data at EHA Shows Promising Durable Tumor Response in Patients with Peripheral T-Cell Lymphoma
-
Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in Patients with Advanced EGFR-Mutated NSCLCDaiichi Sankyo2021-06-04 14:10:11Patritumab Deruxtecan Data at ASCO Demonstrates Tumor Response Across Multiple Resistance Mechanisms in
-
Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO Virtual MeetingDaiichi Sankyo2021-06-04 10:39:54Daiichi Sankyo Advances Science Across Three Lead DXd ADCs with New Data in Multiple Cancers at 2021 ASCO
-
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast CancerDaiichi Sankyo2021-05-07 09:29:00Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease
